Biohaven Financial Statements From 2010 to 2026

BHVN Stock  USD 10.76  0.23  2.09%   
Biohaven Pharmaceutical's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Biohaven Pharmaceutical's valuation are provided below:
Market Capitalization
1.4 B
Earnings Share
(7.52)
We have found one hundred twenty available fundamental signals for Biohaven Pharmaceutical Holding, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to validate Biohaven Pharmaceutical's prevailing fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road.
Check Biohaven Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biohaven Pharmaceutical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 9.5 M, Interest Expense of 1.2 M or Selling General Administrative of 86.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 7.6. Biohaven financial statements analysis is a perfect complement when working with Biohaven Pharmaceutical Valuation or Volatility modules.
  
Build AI portfolio with Biohaven Stock
Check out the analysis of Biohaven Pharmaceutical Correlation against competitors.

Biohaven Pharmaceutical Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets388.4 M707.4 M291.1 M
Slightly volatile
Other Current Liabilities159.9 M152.3 M42.4 M
Slightly volatile
Total Current Liabilities186.2 M177.4 M52.7 M
Slightly volatile
Property Plant And Equipment Net64.9 M61.8 M20.4 M
Slightly volatile
Accounts Payable11.2 M20.7 M8.6 M
Slightly volatile
Cash142.3 M89.2 M151.5 M
Very volatile
Non Current Assets Total46.1 M88.1 M31.8 M
Slightly volatile
Non Currrent Assets Other3.9 M2.8 MM
Slightly volatile
Cash And Short Term Investments303.1 M558.9 M234.5 M
Slightly volatile
Common Stock Shares Outstanding57.6 M104.9 M49.1 M
Slightly volatile
Liabilities And Stockholders Equity388.4 M707.4 M291.1 M
Slightly volatile
Non Current Liabilities Total52.1 M33.7 M38 M
Pretty Stable
Other Current Assets60.2 M57.4 M20.8 M
Slightly volatile
Other Stockholder Equity80 M129.2 M56.2 M
Slightly volatile
Total Liabilities135.8 M220.4 M85.2 M
Slightly volatile
Total Current Assets342.3 M619.2 M259.3 M
Slightly volatile
Common Stock1.1 B1.9 B764.3 M
Slightly volatile
Short and Long Term Debt Total31.3 M32.9 M140.3 M
Very volatile
Other Liabilities2.6 M2.8 M2.1 M
Slightly volatile
Other Assets0.860.9992.8 K
Pretty Stable
Net Receivables2.2 M2.3 M82.2 M
Slightly volatile
Short Term Investments263.2 M444.9 M243.3 M
Slightly volatile
Net Invested Capital317.2 M487 M142 M
Slightly volatile
Property Plant And Equipment Gross47.7 M75.8 M29 M
Slightly volatile
Non Current Liabilities OtherM4.2 M38.6 M
Pretty Stable
Net Working Capital303.8 M441.9 M160.3 M
Slightly volatile
Short Term Debt2.5 M4.4 M1.5 M
Slightly volatile
Intangible Assets18 M16.6 M31.7 M
Slightly volatile
Property Plant Equipment63 M60 M26.1 M
Slightly volatile
Warrants48 M54 M58.9 M
Slightly volatile
Long Term Debt501.4 M564 M615.7 M
Slightly volatile
Common Stock Total Equity1.3 B1.5 B1.6 B
Slightly volatile
Long Term Debt Total501.4 M564 M615.7 M
Slightly volatile
Capital Surpluse135.7 M152.7 M166.7 M
Slightly volatile
Capital Lease Obligations27.7 M42.1 M11.8 M
Slightly volatile
Deferred Long Term Liabilities10.5 M11.8 M12.9 M
Slightly volatile

Biohaven Pharmaceutical Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization9.5 MM2.2 M
Slightly volatile
Interest Expense1.2 M1.2 M12.8 M
Pretty Stable
Selling General Administrative86.3 M102.6 M110 M
Slightly volatile
Other Operating Expenses1.1 BB535.3 M
Slightly volatile
Research Development961 M915.3 M424.1 M
Slightly volatile
Total Operating Expenses1.1 BB535.3 M
Slightly volatile
Cost Of Revenue4.7 M4.5 M1.2 M
Slightly volatile
Reconciled Depreciation9.5 MM2.2 M
Slightly volatile
Selling And Marketing Expenses4.7 M5.3 M5.8 M
Slightly volatile

Biohaven Pharmaceutical Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation65.3 M82.8 M42.1 M
Slightly volatile
Begin Period Cash Flow149.1 M289.9 M99.3 M
Slightly volatile
Capital Expenditures8.1 M4.7 M4.4 M
Slightly volatile
Total Cash From Financing Activities403.3 M779.4 M328.5 M
Slightly volatile
End Period Cash Flow147.1 M92.3 M154.8 M
Pretty Stable
Depreciation9.5 MM2.2 M
Slightly volatile
Change To Netincome362 M344.8 M123.8 M
Slightly volatile
Change To Liabilities6.5 M6.8 M8.9 M
Pretty Stable
Sale Purchase Of Stock9.8 M10.4 M247.2 M
Slightly volatile
Net Borrowings336.4 M378.4 M413 M
Slightly volatile
Cash And Cash Equivalents Changes32.2 M36.3 M39.6 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation0.560.5926.1445
Slightly volatile
Cash Per Share4.274.795.8761
Slightly volatile
Interest Coverage30.1533.9237.0278
Slightly volatile
Income Quality0.770.790.7294
Pretty Stable
Intangibles To Total Assets0.06710.0370.1131
Slightly volatile
Net Debt To EBITDA0.07790.0820.5103
Slightly volatile
Current Ratio7.794.029.9956
Slightly volatile
Debt To Equity0.09440.09940.4674
Slightly volatile
Capex Per Share0.03790.03990.1004
Pretty Stable
Debt To Assets0.120.06840.2408
Slightly volatile
Ebt Per Ebit1.10.95551.0667
Slightly volatile
Long Term Debt To Capitalization0.350.390.4298
Slightly volatile
Total Debt To Capitalization0.170.09150.2851
Slightly volatile
Debt Equity Ratio0.09440.09940.4674
Slightly volatile
Quick Ratio7.794.029.9956
Slightly volatile
Net Income Per E B T1.11.151.0158
Slightly volatile
Cash Ratio0.70.748.4278
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.820.911.0
Slightly volatile
Debt Ratio0.120.06840.2408
Slightly volatile

Biohaven Fundamental Market Drivers

Biohaven Upcoming Events

28th of March 2024
Upcoming Quarterly Report
View
10th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
28th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Biohaven Pharmaceutical Financial Statements

Biohaven Pharmaceutical investors utilize fundamental indicators, such as revenue or net income, to predict how Biohaven Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-34.4 M-32.7 M
Cost Of Revenue4.5 M4.7 M

Pair Trading with Biohaven Pharmaceutical

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biohaven Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biohaven Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.

Moving against Biohaven Stock

  0.49JUMP Leveljump Healthcare CorpPairCorr
  0.49ABP Abpro HoldingsPairCorr
  0.48KURA Kura OncologyPairCorr
  0.39DWTX Dogwood TherapeuticsPairCorr
  0.33IMRN Immuron Ltd ADRPairCorr
The ability to find closely correlated positions to Biohaven Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biohaven Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biohaven Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biohaven Pharmaceutical Holding to buy it.
The correlation of Biohaven Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biohaven Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biohaven Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biohaven Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Biohaven Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biohaven Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biohaven Pharmaceutical Holding Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biohaven Pharmaceutical Holding Stock:
Check out the analysis of Biohaven Pharmaceutical Correlation against competitors.
You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Will Biotechnology sector continue expanding? Could Biohaven diversify its offerings? Factors like these will boost the valuation of Biohaven Pharmaceutical. Projected growth potential of Biohaven fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Biohaven Pharmaceutical data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(7.52)
Return On Assets
(1.06)
Return On Equity
(5.22)
Understanding Biohaven Pharmaceutical requires distinguishing between market price and book value, where the latter reflects Biohaven's accounting equity. The concept of intrinsic value - what Biohaven Pharmaceutical's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Biohaven Pharmaceutical's price substantially above or below its fundamental value.
It's important to distinguish between Biohaven Pharmaceutical's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Biohaven Pharmaceutical should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Biohaven Pharmaceutical's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.